Klonopin (Clonazepam) Onsite Taper

No — and you should not attempt it on your own. You arrive on your current prescribed clonazepam dose. Stopping a benzodiazepine abruptly without supervision is genuinely dangerous, which is precisely why the reduction is done onsite: direct hyperbolic taper or cross-titration to diazepam if patient is also on a short-half-life benzo. A small number of other medications — MAOIs, lithium, tricyclic antidepressants, tramadol and certain QT-prolonging cardiac medications — do still need to be cleared before you arrive, so our medical team reviews your full medication list in advance.

Typically 21–45 days onsite. That range is driven by clonazepam's long half-life — ≈ 30–40 hours — and your baseline dose, usually 0.5–4 mg/day. Reductions are hyperbolic rather than linear, so the schedule follows how you actually respond instead of running to a fixed calendar.

The clonazepam discontinuation profile covers: Seizure risk on abrupt cessation; Severe rebound anxiety and panic; Insomnia, derealization; Autonomic instability — tremor, sweating, BP swings; Protracted withdrawal possible. The onsite protocol bridges the taper with sub-psychoactive iboga total alkaloid (50–150 mg BID) to cover the receptor-occupancy gap as your dose comes down, with symptom-driven support and continuous monitoring throughout.

Long half-life is a feature for stable plasma levels but means symptoms emerge slowly and are harder to attribute. Most outpatient prescribers won't manage tapers below 0.25 mg without compounded liquid. Protracted withdrawal can last months without supervised support.

Yes. Direct hyperbolic taper or cross-titration to diazepam if patient is also on a short-half-life benzo. Hyperbolic step-downs of 5–10% every 7–14 days using compounded liquid. Iboga TA bridge 50–150 mg BID for GABAergic coverage. Continuous cardiac telemetry with EEG at high-risk steps. Seizure-prophylactic magnesium and electrolyte normalization.

A flood dose of ibogaine HCl is only administered once clonazepam has been reduced to a protocol-defined safe threshold and your cardiac screening is still within limits — eligibility is confirmed at that point rather than promised in advance. Ibogaine is an investigational compound, is not approved by the FDA, and results vary between patients. If your medication picture or your screening makes treatment unsafe, we will tell you honestly.